Close Menu

GSK

This story originally ran on Dec. 13.
Biodesix last week presented results from a retrospective analysis of breast cancer patients using its serum proteomic Veristrat diagnostic.

Proteomics firm Cellzome said this week it has won more than €2.3 million ($3.1 million) in grants funding its participation in three separate research projects.

Abbott said this week that it has expanded an existing immunotherapy companion diagnostic development agreement with GlaxoSmithKline to include a new target antigen.

Originally published Nov. 29.
Abbott and GlaxoSmithKline this week formally extended an existing drug/diagnostic codevelopment partnership in the cancer immunotherapy space, setting their sights on a new marker: the PRAME antigen.

By Doug Macron
Alnylam Pharmaceuticals this week unveiled an initiative to apply its RNAi technology to the production of vaccines and announced that GlaxoSmithKline will be its first partner for the platform.

By Ben Butkus
This story has been updated from a version posted Oct. 25 to include comments from a GlaxoSmithKline spokesperson.

Pages

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.